PAVING THE WAY FOR AN ALS TREATMENT
By digging deeper into the cause of ALS, and studying the varying sub-forms of the disease, we are developing precision medications that can effectively treat ALS. The three sub-forms of ALS we are currently developing precision medicine for are:
ALS PATIENTS
ALS has a devastating impact on patients and families. Through DNA analysis and clinical studies, we now know that there are several sub-forms of ALS that should be treated with precision medicine to achieve success. Through our work with stem cells from ALS patients and our close collaborators in the clinic and the world-wide ALS research community we have identified the disease cause for three sub-forms of ALS. A large group of ALS patients have a hyperactive motor system which leads to rapid disease progression. We are developing theraputics to bring this activity back to normal levels. Second, a sub-group of ALS patients have a malfunctioning cellular waste clearance system. QurAlis is developing theraputics to boost this system to clear toxic proteins from the motor neurons in these patients.
For ALS patients in the Tri-state area, please visit the website of the MAC Angels for more information and support: https://www.macangels.org/
OUR MISSION
Our mission at QurAlis is to develop treatments for ALS using precision medicine. ALS can affect anyone. It is a destructive disease which causes muscle paralysis through degeneration of the motor system. An ALS diagnosis is a death sentence to patients, with a predicted life expectancy of about 3 years following diagnosis.
MESSAGES OF HOPE
We can defeat ALS. We have brought world class ALS researchers, doctors and industry experts together to make the right therapies for the right ALS patients and we will not stop until we have succeeded in our mission.
Kasper Roet
Chief Executive Officer
I was introduced only relatively recently to the challenge of ALS and its devastating course in patients. The need for effective treatment is so great that I have become quite obsessed with contributing, both by exploring ALS disease mechanisms in my academic lab and as cofounder of QurAlis, and will not rest until we have made a meaningful impact in halting or preventing the disease.
Clifford J. Woolf
Founder
For the first time in history we have genuine reason to believe we can treat patients with some forms of ALS in the years to come.
Jonathan J. Fleming
Executive Chair
We have known so little in the past about why motor neurons degenerate in ALS that it has been difficult to generate candidate therapeutics with the precision required for them to become actual cures. The transformative genetic and stem cell technologies being employed at QurAlis will allow us to test candidate therapeutics on motor neurons derived from patients during their development, greatly increasing our likelihood of eventual successful in later clinical trials.